kabutan

GNI Group Ltd.(2160) Summary

2160
TSE Growth
GNI Group Ltd.
3,145
JPY
-385
(-10.91%)
Mar 13, 3:30 pm JST
19.73
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
3,282
Mar 13, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.48
Yield
ー%
Margin Trading Ratio
41.51
Stock Price
Mar 13, 2026
Opening Mar 13, 9:12 am
3,200 JPY 20.11 USD
Previous Close Mar 12
3,530 JPY 22.20 USD
High Mar 13, 9:12 am
3,275 JPY 20.58 USD
Low Mar 13, 9:14 am
3,080 JPY 19.36 USD
Volume
2,591,500
Trading Value
8.26B JPY 0.05B USD
VWAP
3188.46 JPY 20.0 USD
Minimum Trading Value
314,500 JPY 1,973 USD
Market Cap
0.18T JPY 1.10B USD
Number of Trades
3,281
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
High
1-Year Average
3,953
1-Year High May 27, 2025
36,454
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 701,800 6,698,600 9.54
Feb 27, 2026 645,400 6,409,700 9.93
Feb 20, 2026 614,400 6,388,300 10.40
Feb 13, 2026 587,600 6,410,100 10.91
Feb 6, 2026 575,200 6,527,500 11.35
Company Profile
GNI Group Ltd. is a biotech venture company focused on drug discovery. It has research and development centers in the United States and China. The company's main product is a drug for idiopathic pulmonary fibrosis. They are also involved in genetic analysis.
Sector
Pharmaceuticals
GNI Group Ltd. operates in both the pharmaceutical and medical device sectors. In its pharmaceutical business, the company sells F351 (Etuary), a treatment for fibrosis, in the Chinese market. They also conduct research, development, manufacturing, and sales of drug compounds targeting lung diseases (interstitial lung diseases), liver diseases, and kidney diseases (chronic kidney disease). The medical device business is based in the United States and focuses on the development, manufacturing, and sales of biomaterials. The group consists of the parent company, 18 consolidated subsidiaries, and 2 affiliated companies. They also provide services such as reagents, designated manufacturing and marketing of medical devices, and domestic clinical trial management.